Related Experiment Video
Updated: Aug 7, 2026

04:10
Robotic-assisted Bronchoscopy Combined with Multimodal Imaging for Targeted Lung Cryobiopsies
Published on: July 19, 2024
Open-lung biopsy guides therapy in children
M T Jaklitsch1, B C Linden, E A Braunlin
1Department of Surgery, University of Minnesota, Minneapolis 55455, USA. mjaklitsch@partners.org
The Annals of Thoracic Surgery
|June 28, 2001
Summary
Pediatric open-lung biopsy is a valuable diagnostic tool, altering workup in 98% of cases. It is recommended for specific complex pediatric lung conditions, especially when other methods fail.
Area of Science:
- Pediatric Pulmonology
- Thoracic Surgery
- Diagnostic Pathology
Background:
- Open-lung biopsy is an uncommon procedure in pediatric patients.
- Current indications and outcomes for pediatric open-lung biopsy are not well-established.
Purpose of the Study:
- To evaluate the modern indications and outcomes of open-lung biopsy in children.
- To compare biopsy practices and outcomes between two distinct time periods.
Main Methods:
- Retrospective review of 64 open-lung biopsies performed on 58 pediatric patients between 1976 and 1996.
- Biopsies were performed for diagnosing parenchymal lung disease, grading vasculopathy in pulmonary hypertension, and evaluating combined pulmonary hypertension and lung disease.
- Data were compared between biopsies performed from 1976-1989 and 1990-1996.
Main Results:
- The 1990-1996 period saw increased use in infants, patients with comorbid disease, and those requiring extracorporeal membrane oxygenation or ventilator support.
- A definitive diagnosis was achieved in 67% of cases, and the procedure altered the diagnostic workup in 98% of cases.
- In-hospital mortality was 30% and morbidity was 11%, with death associated with preoperative ventilator dependence and extracorporeal membrane oxygenation support.
Conclusions:
- Pediatric open-lung biopsy significantly alters diagnostic workup in most cases (98%).
- Recommended for children on extracorporeal membrane oxygenation for over two weeks or with combined pulmonary hypertension and parenchymal lung disease.
- Procedure is less beneficial in immunocompromised pediatric patients.
